Advanced search
Start date
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Phosphodiesterase 4 inhibition restrains muscle proteolysis in diabetic rats by activating PKA and EPAC/Akt effectors and inhibiting FoxO factors

Full text
Arcaro, Carlos Alberto [1] ; Assis, Renata Pires [1] ; Oliveira, Juliana Oriel [1] ; Zanon, Neusa Maria [2] ; Paula-Gomes, Silvia [3] ; Carvalho Navegantes, Luiz Carlos [2] ; Kettelhut, Isis Carmo [2, 4, 5] ; Brunetti, Iguatemy Lourenco [1] ; Baviera, Amanda Martins [1]
Total Authors: 9
[1] Sao Paulo State Univ Unesp, Sch Pharmaceut Sci, Dept Clin Anal, Rodovia Araraquara Jau, Km 01 S-N, Araraquara, SP - Brazil
[2] Univ Sao Paulo, Ribeirao Preto Med Sch, Dept Physiol, Sao Paulo - Brazil
[3] Univ Fed Ouro Preto, Dept Biol Sci, Ouro Preto, MG - Brazil
[4] Univ Sao Paulo, Ribeirao Preto Med Sch, Dept Biochem, Sao Paulo - Brazil
[5] Univ Sao Paulo, Ribeirao Preto Med Sch, Dept Immunol, Sao Paulo - Brazil
Total Affiliations: 5
Document type: Journal article
Source: Life Sciences; v. 278, AUG 1 2021.
Web of Science Citations: 0

Aim: There is growing evidence about the ability of cyclic adenosine monophosphate (cAMP) signaling and nonselective phosphodiesterase (PDE) inhibitors on mitigate muscle atrophy. PDE4 accounts for the major cAMP hydrolyzing activity in skeletal muscles, therefore advances are necessary about the consequences of treatment with PDE4 inhibitors on protein breakdown in atrophied muscles. We postulated that rolipram (selective PDE4 inhibitor) may activate cAMP downstream effectors, inhibiting proteolytic systems in skeletal muscles of diabetic rats. Main methods: Streptozotocin-induced diabetic rats were treated with 2 mg/kg rolipram for 3 days. Changes in the levels of components belonging to the proteolytic machineries in soleus and extensor digitorum longus (EDL) muscles were investigated, as well as cAMP effectors. Key findings: Treatment of diabetic rats with rolipram decreased the levels of atrogin-1 and MuRF-1 in soleus and EDL, and reduced the activities of calpains and caspase-3; these findings partially explains the low ubiquitin conjugates levels and the decreased proteasome activity. The inhibition of muscle proteolysis may be occurring due to phosphorylation and inhibition of forkhead box O (FoxO) factors, probably as a consequence of the increased cAMP levels, followed by the activation of PKA and Akt effectors. Akt activation may be associated with the increased levels of exchange protein directly activated by cAMP (EPAC). As a result, rolipram treatment spared muscle mass in diabetic rats. Significance: The antiproteolytic responses associated with PDE4 inhibition may be helpful to motivate future investigations about the repositioning of PDE4 inhibitors for the treatment of muscle wasting conditions. (AU)

FAPESP's process: 14/12202-0 - Role of cyclic AMP-dependent effectors, PKA and EPAC, in the control of the Calcium-dependent proteolysis, caspase-mediated proteolysis and ubiquitin-proteasome system in diabetes muscle atrophy
Grantee:Carlos Alberto Arcaro Filho
Support Opportunities: Scholarships in Brazil - Doctorate
FAPESP's process: 13/18861-2 - EPAC/AKT/FoxO signaling and the control of the caspase-mediated proteolytic process and of the ubiquitin-proteasome system in diabetes muscle atrophy
Grantee:Amanda Martins Baviera
Support Opportunities: Regular Research Grants